274 related articles for article (PubMed ID: 21188144)
1. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.
Pennisi A; Ling W; Li X; Khan S; Wang Y; Barlogie B; Shaughnessy JD; Yaccoby S
PLoS One; 2010 Dec; 5(12):e15233. PubMed ID: 21188144
[TBL] [Abstract][Full Text] [Related]
2. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
[TBL] [Abstract][Full Text] [Related]
3. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
Yaccoby S; Ling W; Zhan F; Walker R; Barlogie B; Shaughnessy JD
Blood; 2007 Mar; 109(5):2106-11. PubMed ID: 17068150
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
Yaccoby S; Wezeman MJ; Zangari M; Walker R; Cottler-Fox M; Gaddy D; Ling W; Saha R; Barlogie B; Tricot G; Epstein J
Haematologica; 2006 Feb; 91(2):192-9. PubMed ID: 16461303
[TBL] [Abstract][Full Text] [Related]
5. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.
Qiang YW; Shaughnessy JD; Yaccoby S
Blood; 2008 Jul; 112(2):374-82. PubMed ID: 18344425
[TBL] [Abstract][Full Text] [Related]
6. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration.
Jilka RL; Almeida M; Ambrogini E; Han L; Roberson PK; Weinstein RS; Manolagas SC
Aging Cell; 2010 Oct; 9(5):851-67. PubMed ID: 20698835
[TBL] [Abstract][Full Text] [Related]
7. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
8. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.
Li X; Ling W; Pennisi A; Wang Y; Khan S; Heidaran M; Pal A; Zhang X; He S; Zeitlin A; Abbot S; Faleck H; Hariri R; Shaughnessy JD; van Rhee F; Nair B; Barlogie B; Epstein J; Yaccoby S
Stem Cells; 2011 Feb; 29(2):263-73. PubMed ID: 21732484
[TBL] [Abstract][Full Text] [Related]
9. Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation.
Zhu Q; Zhou X; Zhu M; Wang Q; Goltzman D; Karaplis A; Miao D
J Bone Miner Res; 2013 Sep; 28(9):1898-911. PubMed ID: 23716486
[TBL] [Abstract][Full Text] [Related]
10. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms.
Jilka RL; O'Brien CA; Bartell SM; Weinstein RS; Manolagas SC
J Bone Miner Res; 2010 Nov; 25(11):2427-37. PubMed ID: 20533302
[TBL] [Abstract][Full Text] [Related]
11. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.
Pennisi A; Ling W; Li X; Khan S; Shaughnessy JD; Barlogie B; Yaccoby S
Blood; 2009 Aug; 114(9):1803-12. PubMed ID: 19597185
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
Pennisi A; Li X; Ling W; Khan S; Gaddy D; Suva LJ; Barlogie B; Shaughnessy JD; Aziz N; Yaccoby S
Br J Haematol; 2009 Jun; 145(6):775-87. PubMed ID: 19388929
[TBL] [Abstract][Full Text] [Related]
13. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.
Weinstein RS; Jilka RL; Almeida M; Roberson PK; Manolagas SC
Endocrinology; 2010 Jun; 151(6):2641-9. PubMed ID: 20410195
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of high dietary calcium and exogenous parathyroid hormone in promoting osteoblastic bone formation in mice.
Feng Y; Zhou M; Zhang Q; Liu H; Xu Y; Shu L; Zhang J; Miao D; Ren Y
Br J Nutr; 2015 Mar; 113(6):909-22. PubMed ID: 25744000
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
16. Differential transcriptional effects of PTH and estrogen during anabolic bone formation.
von Stechow D; Zurakowski D; Pettit AR; Müller R; Gronowicz G; Chorev M; Otu H; Libermann T; Alexander JM
J Cell Biochem; 2004 Oct; 93(3):476-90. PubMed ID: 15372627
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.
Li X; Ling W; Khan S; Yaccoby S
J Bone Miner Res; 2012 Aug; 27(8):1635-48. PubMed ID: 22460389
[TBL] [Abstract][Full Text] [Related]
18. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
19. Osteoblastogenesis and tumor growth in myeloma.
Yaccoby S
Leuk Lymphoma; 2010 Feb; 51(2):213-20. PubMed ID: 20038269
[TBL] [Abstract][Full Text] [Related]
20. Propranolol Promotes Bone Formation and Limits Resorption Through Novel Mechanisms During Anabolic Parathyroid Hormone Treatment in Female C57BL/6J Mice.
Treyball A; Bergeron AC; Brooks DJ; Langlais AL; Hashmi H; Nagano K; Barlow D; Neilson RJ; Roy TA; Nevola KT; Houseknecht KL; Baron R; Bouxsein ML; Guntur AR; Motyl KJ
J Bone Miner Res; 2022 May; 37(5):954-971. PubMed ID: 35122666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
